Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including oligodendrocyte progenitor cells; strongest in monocytes | 0.75 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 13 pathways; mostly protein handling | 0.90 |
Knock down and overexpress VCAN in oligodendrocytes; measure proteasome activity and the load of ubiquitinated protein and α-synuclein uptake and myelin basic protein output under oxidative stress.
- Cell type
- oligodendrocytes
- Direction
- Both arms: public data does not say which way helps.
- Molecular readout
- proteasome activity and the load of ubiquitinated protein
- Functional readout
- α-synuclein uptake and myelin basic protein output under oxidative stress
- Rule-out
- If neither arm moves proteasome activity by 20% or more against non-targeting and empty-vector controls, across three independent differentiations, the hypothesis is wrong.
- Lab request
- CRISPRi knockdown and lentiviral overexpression of VCAN in iPSC-derived oligodendrocytes; n = 3 differentiations; readouts: proteasome activity and the load of ubiquitinated protein; α-synuclein uptake and myelin basic protein output under oxidative stress. Controls: non-targeting guide, empty vector. About 8 to 10 weeks, most of it differentiation.
Sealed predictions
- VCAN in dopamine neurons, braak-0.04 (p 0.927) → +0.37 (p 0.323)receipt 11564
- VCAN in oligodendrocytes, braak-0.69 (p 0.042) → -0.44 (p 0.237)receipt 11563
Swarm cases
receipt 11564: VCAN in dopamine neurons, braak
- power
- full sample +0.21 (p 0.413, n 18), 95% CI -0.29 to +0.61. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.23 (p 0.365, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.28 (p 0.269, n 18). could be the mix.
- skeptic
- leave-one-out range +0.12 to +0.33, sign flips 0; without severely affected donors +0.21 (p 0.413, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for VCAN in dopamine neurons.
case closed: nothing better to follow up.
receipt 11563: VCAN in oligodendrocytes, braak
- power
- full sample -0.39 (p 0.107, n 18), 95% CI -0.73 to +0.09. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.40 (p 0.103, n 18). does not hold up.
- composition
- oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.40 (p 0.099, n 18). could be the mix.
- skeptic
- leave-one-out range -0.51 to -0.32, sign flips 0; without severely affected donors -0.39 (p 0.107, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for VCAN in oligodendrocytes.
case closed: nothing better to follow up.
Receipts
loading the receipts